3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Neuroendocrine Tumors
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
Temozolomide
6
Cyclophosphamide
4
antineoplaston AS 2-1
3
antineoplaston A10
3
Radiotherapy
3
Filgrastim
3
sargramostim
2
aldesleukin
2
Vincristine
2
Thalidomide
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Donepezil
2
Cisplatin
2
Carmustine
2
Bevacizumab
2
veliparib
1
trametinib
1
temsirolimus
1
surufatinib
1
spartalizumab
1
sonidegib
1
ribociclib
1
reolysin
1
plerixafor
1
ganitumab
1
fosbretabulin
1
entinostat
1
dactolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neuroectodermal Tumors, Primitive
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts